摘要： 肝细胞癌是我国六大恶性肿瘤之一,病死率高。目前最广泛应用的甲胎蛋白和超声筛查仍会漏诊2/3的患者,疾病早期诊断率低。近年来随着对肝细胞癌诊断标志物的不断探索,发现存在于体液中且以稳定的共价闭环结构存在的环状RNA(circRNA)对肝细胞癌具有潜在的早期诊断价值。本文就circRNA的功能及在HCC早期诊断中的研究进展做一综述。
黄梦, 钱晓寒, 杨丽华. 环状RNA应用于肝细胞癌无创早期诊断的研究进展[J]. 肝脏, 2023, 28(6): 720-724.
| [1] Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021, 71(3):209-249. [2] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet, 2018, 391(10127):1301-1314. [3] McGlynn KA, London WT. The global epidemiology of hepatocellular carcinoma: present and future. Clin Liver Dis, 2011, 15(2):223-243, vii-x. [4] Galle PR, Foerster F, Kudo M, et al. Biology and significance of alpha-fetoprotein in hepatocellular carcinoma. Liver Int, 2019, 39(12):2214-2229. [5] Wang S, Zhang K, Tan S, et al. Circular RNAs in body fluids as cancer biomarkers: the new frontier of liquid biopsies, Mol Cancer, 2021, 20(1):13. [6] Chen LL, Yang L. Regulation of circRNA biogenesis, RNA Biol, 2015, 12(4):381-388. [7] Jeck WR, Sorrentino JA, Wang K, et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA, 2013, 19(2):141-157. [8] Memczak S, Jens M, Elefsinioti A, et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature, 2013, 495(7441):333-338. [9] Meng X, Li X, Zhang P, et al. Circular RNA: an emerging key player in RNA world. Brief Bioinform, 2017, 18(4):547-557. [10] Thomson DW, Dinger ME. Endogenous microRNA sponges: evidence and controversy. Nat Rev Genet, 2016, 17(5):272-283. [11] Huang A, Zheng H, Wu Z, et al. Circular RNA-protein interactions: functions, mechanisms, and identification. Theranostics, 2020, 10(8):3503-3517. [12] Zhang M, Huang N, Yang X, et al. A novel protein encoded by the circular form of the SHPRH gene suppresses glioma tumorigenesis, Oncogene, 2018, 37(13):1805-1814. [13] Li Z, Huang C, Bao C, et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol, 2015, 22(3):256-264. [14] Tang X, Ren H, Guo M, et al. Review on circular RNAs and new insights into their roles in cancer. Comput Struct Biotechnol J, 2021, 19:910-928. [15] Lei D, Wang T. circSYPL1 promotes the proliferation and metastasis of hepatocellular carcinoma via the upregulation of EZH2 expression by competing with hsa-miR-506-3p. J Oncol, 2022, 2022:2659563. [16] Sun S, Gao J, Zhou S, et al. A novel circular RNA circ-LRIG3 facilitates the malignant progression of hepatocellular carcinoma by modulating the EZH2/STAT3 signaling. J Exp Clin Cancer Res, 2020, 39(1):252. [17] Chen Y, Ling Z, Cai X, et al. Activation of YAP1 by N6-methyladenosine-modified circCPSF6 drives malignancy in hepatocellular carcinoma. Cancer Res, 2022, 82(4):599-614. [18] Liu W, Zheng L, Zhang R, et al. Circ-ZEB1 promotes PIK3CA expression by silencing miR-199a-3p and affects the proliferation and apoptosis of hepatocellular carcinoma. Mol Cancer, 2022, 21(1):72. [19] Yu Q, Chen W, Li Y, et al. The novel circular RNA HIPK3 accelerates the proliferation and invasion of hepatocellular carcinoma cells by sponging the micro RNA-124 or micro RNA-506/pyruvate dehydrogenase kinase 2 axis. Bioengineered, 2022, 13(3):4717-4729. [20] Jiang B, Tian M, Li G, et al. circEPS15 Overexpression in hepatocellular carcinoma modulates tumor invasion and migration. Front Genet, 2022, 13:804848. [21] Luo YY, Tao KG, Lu YT, et al. Hsa_Circ_0098181 suppresses hepatocellular carcinoma by sponging miR-18a-3p and targeting PPARA. Front Pharmacol, 2022, 13:819735. [22] Liu H, Lan T, Li H, et al. Circular RNA circDLC1 inhibits MMP1-mediated liver cancer progression via interaction with HuR. Theranostics, 2021, 11(3):1396-1411. [23] Mu Q, Lv Y, Luo C, et al. Research progress on the functions and mechanism of circRNA in cisplatin resistance in tumors. Front Pharmacol, 2021, 12:709324. [24] Xu J, Wan Z, Tang M, et al. N6-methyladenosine-modified CircRNA-SORE sustains sorafenib resistance in hepatocellular carcinoma by regulating β-catenin signaling. Mol Cancer, 2020, 19(1):163. [25] Li Y, Zhang Y, Zhang S, et al. circRNA circARNT2 suppressed the sensitivity of hepatocellular carcinoma cells to cisplatin by targeting the miR-155-5p/PDK1 axis. Mol Ther Nucleic Acids, 2020, 23:244-254. [26] Zhang P, Sun H, Wen P, et al. circRNA circMED27 acts as a prognostic factor and mediator to promote lenvatinib resistance of hepatocellular carcinoma. Mol Ther Nucleic Acids, 2021, 27:293-303. [27] Tzartzeva K, Obi J, Rich NE, et al. Surveillance imaging and alpha fetoprotein for early detection of hepatocellular carcinoma in patients with cirrhosis: A meta-analysis. Gastroenterology, 2018, 154(6):1706-1718.e1. [28] Yoon JH, Lee JM, Lee DH, et al. A comparison of biannual two-phase low-dose liver CT and US for HCC surveillance in a group at high risk of HCC development. Liver Cancer, 2020, 9(5):503-517. [29] Gupta P, Soundararajan R, Patel A, et al. Abbreviated MRI for hepatocellular carcinoma screening: A systematic review and meta-analysis. J Hepatol, 2021, 75(1):108-119. [30] Colli A, Nadarevic T, Miletic D, et al. Abdominal ultrasound and alpha-foetoprotein for the diagnosis of hepatocellular carcinoma?in adults with chronic liver disease. Cochrane Database Syst Rev, 2021, 4(4):CD013346. [31] Best J, Bilgi H, Heider D, et al. The GALAD scoring algorithm based on AFP, AFP-L3, and DCP significantly improves detection of BCLC early stage hepatocellular carcinoma. Z Gastroenterol, 2016, 54(12):1296-1305. [32] Yamamoto Y, Kondo S, Matsuzaki J, et al. Highly sensitive circulating microrna panel for accurate detection of hepatocellular carcinoma in patients with liver disease. Hepatol Commun, 2019, 4(2):284-297. [33] Li Z, Zhou Y, Yang G, et al. Using circular RNA SMARCA5 as a potential novel biomarker for hepatocellular carcinoma. Clin Chim Acta, 2019, 492:37-44. [34] El Sharkawi FZ, Awad MS, Elagawy W, et al. Circular RNAs 0064286 and 0000475: Potential diagnostic biomarkers in hepatocellular carcinoma. Asian Pac J Cancer Prev, 2021, 22(9):3039-3044. [35] Zhang X, Xu Y, Qian Z, et al. circRNA_104075 stimulates YAP-dependent tumorigenesis through the regulation of HNF4a and may serve as a diagnostic marker in hepatocellular carcinoma. Cell Death Dis, 2018, 9(11):1091. [36] Jiang Z, Shen L, Wang S, et al. Hsa_circ_0028502 and hsa_circ_0076251 are potential novel biomarkers for hepatocellular carcinoma. Cancer Med, 2019, 8(17):7278-7287. [37] Matboli M, Shafei AE, Ali MA, et al. circRNAs (hsa_circ_00156, hsa_circ _000224, and hsa_circ _000520) are novel potential biomarkers in hepatocellular carcinoma. J Cell Biochem, 2018, 120(5):7711-7724. [38] Sun XH, Wang YT, Li GF, et al. Serum-derived three-circRNA signature as a diagnostic biomarker for hepatocellular carcinoma. Cancer Cell Int, 2020, 20:226. [39] Yu J, Ding WB, Wang MC, et al. Plasma circular RNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma: A large-scale, multicenter study. Int J Cancer, 2020, 146(6):1754-1763. [40] Zhang Y, Li J, Cui Q, et al. Circular RNA hsa_circ_0006091 as a novel biomarker for hepatocellular carcinoma. Bioengineered, 2022, 13(2):1988-2003. [41] Liu R, Li Y, Wu A, et al. Identification of plasma hsa_circ_0005397 and combined with serum afp, afp-l3 as potential biomarkers for hepatocellular carcinoma. Front Pharmacol, 2021, 12:639963. [42] Qiao GL, Chen L, Jiang WH, et al. Hsa_circ_0003998 may be used as a new biomarker for the diagnosis and prognosis of hepatocellular carcinoma. Onco Targets Ther, 2019, 12:5849-5860. [43] Zhang X, Zhou H, Jing W, et al. The circular RNA hsa_circ_0001445 regulates the proliferation and migration of hepatocellular carcinoma and May Serve as a diagnostic biomarker. Dis Markers, 2018, 2018:3073467. |
| [1] | 陈倩倩, 杨玥, 倪文婧, 芮法娟, 施军平, 李婕. 非酒精性脂肪性肝病相关肝细胞癌的防治策略研究进展[J]. 肝脏, 2023, 28(6): 639-643. |
| [2] | 马伯恒, 王霞, 吴颖. 肉瘤样肝细胞癌血清生化指标、病理特征及手术疗效评估[J]. 肝脏, 2023, 28(6): 676-679. |
| [3] | 靳志恩, 徐攀, 袁宏伟, 徐敬江. HCV感染者接受直接抗病毒药物治疗肝细胞癌风险变化[J]. 肝脏, 2023, 28(6): 680-682. |
| [4] | 肖滢, 吴治念, 王亚东. 肝素非抗凝作用在肝病应用中的研究进展[J]. 肝脏, 2023, 28(6): 730-733. |
| [5] | 武超玉. 以发热为主要表现的肝脏原发性平滑肌肉瘤1例[J]. 肝脏, 2023, 28(6): 741-742. |
| [6] | 黄孙桦, 刘建东, 黄罡. 肝细胞癌免疫治疗生物标志物的研究进展[J]. 肝脏, 2023, 28(5): 510-512. |
| [7] | 陈克敏. 成像生物标记物预测肝细胞癌免疫治疗反应的研究进展[J]. 肝脏, 2023, 28(5): 513-514. |
| [8] | 邓霖霖, 石清兰, 韦华柱, 莫展进, 黄祖鸿. 乙型肝炎病毒相关肝细胞癌高危因素分析[J]. 肝脏, 2023, 28(5): 614-617. |
| [9] | 范芯铷, 刘铭佳, 王庆, 汪慧. 原发性肝癌的发病机制及治疗进展[J]. 肝脏, 2023, 28(4): 391-392. |
| [10] | 钱厚龙, 李阳, 朱翔, 路逵. 卡瑞利珠单抗联合仑伐替尼治疗不可切除肝细胞癌的疗效和安全性[J]. 肝脏, 2023, 28(4): 452-456. |
| [11] | 朱加作, 赵吉光, 程志原. 不同剂量阿帕替尼联合卡瑞利珠单抗对肝癌患者晚期治疗的疗效及安全性观察[J]. 肝脏, 2023, 28(4): 457-460. |
| [12] | 杨柏帅, 袁敏. 肝细胞癌的介入治疗[J]. 肝脏, 2023, 28(3): 279-280. |
| [13] | 胡伯斌, 王荣明, 梁蘅恺, 韦璐, 黎清梅, 苏土梅, 殷倩冰, 江建宁. ESPL1基因在肝细胞癌组织中的表达及其在预后评估中的作用[J]. 肝脏, 2023, 28(3): 285-289. |
| [14] | 苏佩华, 魏梦平, 赵彩彦. 慢性乙型肝炎合并非酒精性脂肪性肝病对肝细胞癌发生及全因死亡影响的meta分析[J]. 肝脏, 2023, 28(3): 299-304. |
| [15] | 范芯铷, 晏梓钧, 王庆, 汪慧. 青年消瘦型非酒精性脂肪性肝病相关肝细胞癌2例[J]. 肝脏, 2023, 28(2): 151-154. |
| 阅读次数 | ||||||
|
全文 |
|
|||||
|
摘要 |
|
|||||
